PMID- 32908558
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Protective Effects of Yiqi Xingnao Oral Liquid on Cerebral Ischemia-Reperfusion 
      Injury in Rats and Its Related Mechanisms.
PG  - 3268047
LID - 10.1155/2020/3268047 [doi]
LID - 3268047
AB  - PURPOSE: This study aimed to investigate the effects of different concentrations 
      of Yiqi Xingnao (YQXN) oral liquid on cerebral ischemia/reperfusion (I/R) injury 
      in rats and YQXN's related mechanisms. METHODS: Rats were pretreated with 
      3 mL/kg, 6 mL/kg, and 12 mL/kg YQXN and Naoxuekang capsule (NXK). Afterwards, 
      cerebral I/R model rats were established by a middle cerebral artery occlusion 
      surgery. Neurological deficits, histopathology, and cerebral infarction volume 
      were used to evaluate the effects of YQXN. Evans blue and terminal 
      deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining 
      were utilized to determine the blood-brain barrier permeability and cell 
      apoptosis, respectively. The expression of VEGF and Bcl-2 was analyzed by 
      real-time quantification PCR (RT-qPCR) and western blot. The malondialdehyde 
      (MDA) content and superoxide dismutase (SOD) activity were measured using 
      corresponding assay kits. RESULTS: The rats pretreated with YQXN had improved 
      neurological deficits, reduced infarct volume and blood-brain barrier 
      permeability, and ameliorated ischemia-induced morphology change in injured brain 
      tissues. TUNEL staining results showed that different concentrations of YQXN 
      inhibited cell apoptosis of neurocytes in I/R rats. Besides, RT-qPCR and western 
      blot analyses indicated that the expression levels of VEGF and Bcl-2 were 
      significantly upregulated by YQXN compared with the I/R group (P < 0.05). 
      Additionally, rats in the I/R group had lower SOD activity and higher MDA content 
      than those in the sham-operated group, while their levels were recovered by YQXN 
      (P < 0.05). CONCLUSION: YQXN could alleviate cerebral I/R injury by suppressing 
      blood-brain barrier permeability, neuron apoptosis, and oxidative stress, 
      promoting angiogenesis.
CI  - Copyright (c) 2020 Tao Pang et al.
FAU - Pang, Tao
AU  - Pang T
AD  - Department of Pharmacy, Changzheng Hospital, Navy Medical University (Second 
      Military Medical University), Shanghai 200003, China.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Department of Traditional Chinese Medicine, Changzheng Hospital, Navy Medical 
      University (Second Military Medical University), Shanghai 200003, China.
FAU - Zhang, Feng
AU  - Zhang F
AD  - Department of Pharmacy, Changzheng Hospital, Navy Medical University (Second 
      Military Medical University), Shanghai 200003, China.
FAU - Piao, Shujuan
AU  - Piao S
AD  - Department of Pharmacy, Changzheng Hospital, Navy Medical University (Second 
      Military Medical University), Shanghai 200003, China.
FAU - Yang, Hong
AU  - Yang H
AD  - Department of Pharmacy, Changzheng Hospital, Navy Medical University (Second 
      Military Medical University), Shanghai 200003, China.
FAU - Jiao, Jianpeng
AU  - Jiao J
AD  - Department of Traditional Chinese Medicine, Changzheng Hospital, Navy Medical 
      University (Second Military Medical University), Shanghai 200003, China.
FAU - Tang, Lei
AU  - Tang L
AD  - Department of Pharmacy, Changzheng Hospital, Navy Medical University (Second 
      Military Medical University), Shanghai 200003, China.
FAU - Lu, Wenquan
AU  - Lu W
AUID- ORCID: 0000-0003-2590-6389
AD  - Department of Pharmacy, Changzheng Hospital, Navy Medical University (Second 
      Military Medical University), Shanghai 200003, China.
FAU - Chen, Wansheng
AU  - Chen W
AUID- ORCID: 0000-0002-7278-6132
AD  - Department of Pharmacy, Changzheng Hospital, Navy Medical University (Second 
      Military Medical University), Shanghai 200003, China.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7468675
COIS- All authors declare they have no conflicts of interest.
EDAT- 2020/09/11 06:00
MHDA- 2020/09/11 06:01
PMCR- 2020/08/25
CRDT- 2020/09/10 05:35
PHST- 2020/03/14 00:00 [received]
PHST- 2020/07/29 00:00 [accepted]
PHST- 2020/09/10 05:35 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/11 06:01 [medline]
PHST- 2020/08/25 00:00 [pmc-release]
AID - 10.1155/2020/3268047 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Aug 25;2020:3268047. doi: 
      10.1155/2020/3268047. eCollection 2020.